A Comparison of Insulin Adherence in Patients with Type 2 Diabetes Initiating Therapy with Insulin Detemir in a Pen Device or NPH Insulin in a Vial

被引：0
|
作者：
Buysman, Erin K.
Conner, Christopher
Liu, Fang
Aagren, Mark
Bouchard, Jonathan
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2363-PO
引用
收藏
页码：A628 / A628
页数：1
相关论文
共 50 条
  • [1] A COMPARISON OF INSULIN ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES INITIATING THERAPY WITH INSULIN DETEMIR FLEXPEN® OR NPH INSULIN IN A VIAL
    Buysman, E.
    Aagren, M.
    Liu, F.
    Bouchard, J.
    Conner, C.
    VALUE IN HEALTH, 2011, 14 (07) : A481 - A481
  • [2] A COMPARISON OF INSULIN ADHERENCE IN PATIENTS WITH TYPE-2 DIABETES INITIATING THERAPY WITH INSULIN DETEMIR FLEXPEN® OR NPH INSULIN IN A VIAL
    Buysman, E.
    Conner, C.
    Liu, F.
    Aagren, M.
    Bouchard, J.
    VALUE IN HEALTH, 2011, 14 (03) : A98 - A98
  • [3] Impact of initiating or converting to treatment with an insulin aspart analog pen on medication adherence in type 2 diabetes patients on vial/syringe insulin
    Balu, S.
    Lee, W. C.
    Cobden, D.
    Joshi, A., V
    Pashos, C. L.
    VALUE IN HEALTH, 2007, 10 (03) : A68 - A68
  • [4] Comparison of adherence and cost outcomes in patients with type 2 diabetes initiating rapid acting insulin analogue with a prefilled pen versus vial/syringe
    Lee, L. J.
    Li, Q.
    Reynolds, M. W.
    Sarsour, K.
    Corrigan, S. M.
    DIABETOLOGIA, 2010, 53
  • [5] Therapy class conversion in patients with type 2 diabetes: Economic evaluation of insulin detemir and NPH
    Valentine, W. J.
    Cobden, D.
    Palmer, A. J.
    Wagner, S.
    Roze, S.
    VALUE IN HEALTH, 2006, 9 (06) : A230 - A230
  • [6] Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes
    Robertson, K. J.
    Schoenle, E.
    Gucev, Z.
    Mordhorst, L.
    Gall, M. -A.
    Ludvigsson, J.
    DIABETIC MEDICINE, 2007, 24 (01) : 27 - 34
  • [7] Risk of breast cancer in women initiating insulin glargine compared with insulin detemir Or NPH insulin
    Bradley, Marie C.
    Chillarige, Yoganand
    Lee, Hana
    Wu, Xiyuan
    Bright, Patricia
    Parulekar, Shruti
    Wernecke, Michael
    Soukup, Mat
    Kelman, Jeffrey A.
    Graham, David J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 146 - 146
  • [8] Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients
    Pan, Chang-Yu
    Sinnassamy, Patrick
    Chung, Kab-Do
    Kim, Kwang-Won
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 (01) : 111 - 118
  • [9] Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in subjects with type 1 diabetes
    Heise, T
    Nosek, L
    Draeger, E
    Stender, A
    Ronn, BB
    Kapitza, C
    Heinemann, L
    DIABETES, 2003, 52 : A121 - A121
  • [10] Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes
    Heise, T
    Nosek, L
    Ronn, BB
    Endahl, L
    Heinemann, L
    Kapitza, C
    Draeger, E
    DIABETES, 2004, 53 (06) : 1614 - 1620
12345